Mean reduction in triglycerides (45–62%), total cholesterol (17–26%), non-HDL cholesterol (21–36%), LDL cholesterol (11–27%), HbA1c (0.7–1.6%), increase in HDL cholesterol (up to 9%); Improvement in ALT and fatty liver scores; No significant changes in body weight; No significant adverse events reported. This evidence concerns the gene GPT and Hepatic steatosis.